J&J’s ketamine-derived nasal spray approved by FDA to treat depression By Daniella Genovese, Fox Business Published Jan. 21, 2025, 10:00 p.m. ET ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

UNDATED (CNN/CNN Newsource/WKRC) - The FDA just approved a ketamine-derived nasal spray for helping to treat depression. The Food and Drug Administration (FDA) has approved Spravato, a nasal spray ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

The nasal spray was first approved by the FDA in 2019 as a supplemental treatment, along with an oral medication, for the approximately one-third of people with MDD who struggle with treatment ...

The U.S. Food and Drug Administration approved Johnson & Johnson‘s ketamine-based nasal spray as a standalone therapy for adults with treatment-resistant depression. The spray, Spravato, first ...

This week, the FDA approved esketamine, the first nasal spray to treat depression in adults who have tried other antidepressant medications without success. Esketamine, which the FDA approved to ...

The U.S. Food and Drug Administration (FDA) this week approved a new treatment developed by Janssen Pharmaceuticals, Inc. Esketamine will be marketed under the brand name Spravato as a nasal spray.

Spravato nasal spray has been FDA approved to treat depression. Here's how the esketamine spray works, esketamine vs. ketamine, and potential risks.

Ketamine, often associated with street drug "Special-K" and also a hospital-grade anesthetic, could be a breakthrough, fast-acting therapy for major depression in a nasal spray form, according to ...